Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Yijun LiZhifeng ChengWeiPing LuPing LiHongwei JiangJing YangJing XuCheng ZhangLili ZhangYao WangFang BianWeiying GuoXuefeng YuXiaopan ChenDong ZhaoBo FengShen QuJie QinYifei ZhangLin WangHong ChengYi-Ming MuPublished in: Diabetes, obesity & metabolism (2023)
In obese Chinese adults without diabetes, once-daily subcutaneous noiiglutide significantly reduced body week at week 24 compared with placebo, and had a manageable safety profile, primarily involving gastrointestinal disorders.
Keyphrases
- placebo controlled
- double blind
- body weight
- type diabetes
- phase iii
- clinical trial
- phase ii
- glycemic control
- adipose tissue
- weight loss
- cardiovascular disease
- study protocol
- metabolic syndrome
- phase ii study
- obese patients
- physical activity
- randomized controlled trial
- bariatric surgery
- insulin resistance
- radiation therapy
- open label